Table 3.
Characteristics and mutation status of KRAS and EGFR in BRAF-V600E negative thyroid carcinoma samples
| Characteristics | KRAS | EGFR | ||
|---|---|---|---|---|
| +, n (%) | −, n (%) | +, n (%) | −, n (%) | |
| Frequency | 19 (41.3) | 27 (58.7) | 21 (45.7) | 25 (54.3) |
| Male | 15 (78.9) | 17 (63.0) | 13 (61.9) | 27 (45.8) |
| Female | 4 (21.1) | 10 (37.0) | 8 (38.1) | 32 (54.2) |
| Mean age, years ± standard deviation | 55.5 ± 12.4 | 51.9 ± 12.9 | 50.5 ± 12.5 | 55.7 ± 12.6 |
| Thyroid carcinoma variants | ||||
| Papillary thyroid carcinoma | 9 (47.4) | 17 (63.0) | 15 (71.4) | 11 (44) |
| Classic variant | 2 (10.5) | 4 (14.8) | 4 (19.0) | 2 (8.0) |
| Follicular variant | 3 (15.8) | 11 (40.7) | 9 (42.9) | 5 (20.0) |
| Tall cell variant | 3 (15.8) | 0 | 0 | 3 (12.0) |
| Columnar cell variant | 1 (5.3) | 2 (7.4) | 2 (9.5) | 1 (5.0) |
| Follicular carcinoma | 10 (52.6) | 10 (37.0) | 6 (28.6) | 14 (56) |
| Anaplastic carcinoma | 0 | 0 | 0 | 0 |
| Capsular invasion+ | 16 (84.2) | 22 (81.5) | 17 (81.0) | 21 (85.0) |
| Capsular invasion− | 3 (15.8) | 5 (18.5) | 4 (19.0) | 4 (15.0) |
| Vascular invasion+ | 15 (78.9) | 17 (63.0) | 12 (57.1) | 20 (80.0) |
| Vascular invasion− | 4 (21.1) | 10 (37.0) | 9 (42.9) | 5 (20.0) |